Results 81 to 90 of about 581 (153)

Effects of solriamfetol on cognition in participants with cognitive impairment associated with excessive daytime sleepiness in obstructive sleep apnea: SHARP study results

Introduction: The SHARP study evaluated whether solriamfetol improves cognitive function in patients with obstructive sleep apnea (OSA) experiencing excessive daytime sleepiness (EDS) and extant impaired cognition.
Bates, J., Tabuteau, H., Leary, E. B, Van Dongen, Hans P. A., Drake, Christopher, Bogan, Richard, Rosenberg, R., Streicher, C., Kwak, H., Jaeger, Judith   +9 more
core   +1 more source

Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea : a network meta-analysis

: Background Obstructive sleep apnoea (OSA) is a common chronic respiratory disease associated with a high burden of disabilities related to sleepiness and reduced quality of life.
Pepin, Jean-Louis, Craig, Sonya, Dauvilliers, Yves, Joyeux-Faure, Marie, Causse, Christian, Verbraecken, Johan, Bonsignore, Maria R., Lehert, Philippe, Ben Messaoud, Raoua, Barbe, Ferran, Asin, Jerryll, Randerath, Winfried   +11 more
core   +2 more sources

A validated Rhodamine B fluorescence quenching spectrofluorimetric method for solriamfetol determination in human plasma with pharmacokinetic application. [PDF]

RSC Adv
Serag A, Felemban RA, Al Khzem AH, Alturki MS, Aldawsari MF, Alosaimi ME, Abduljabbar MH, Almalki AH.   +7 more
europepmc   +1 more source

The Role of Pharmacotherapy for Excessive Daytime Sleepiness in OSA: A Changing Landscape? [PDF]

CHEST Pulm
Chapman JL, Tai JE, Harper C, Grunstein RR, Yee BJ.   +4 more
europepmc   +1 more source

Comparative efficacy, safety, and dosing convenience of wake-promoting agents and sodium oxybate formulations for narcolepsy: a systematic review and network meta-analysis

Purpose We conducted a network meta-analysis (NMA) to rank the comparative efficacy, safety, and dosing convenience of novel and traditional narcolepsy therapies. Methods
Zhengtian Gu, Qingqing Jiang
core   +1 more source

Development of Narcolepsy Type 1 Following COVID-19 Infection in a Patient Previously Diagnosed With Idiopathic Hypersomnia: A Case Report. [PDF]

Cureus
Pham B, Memon T.
europepmc   +1 more source

Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial. [PDF]

CNS Drugs
Cheng H, Deng L, Meng Z, Zhang W, Chen T, Chen R, Tang S, Lv Y, Su X, Liu Z, Zhang X, Wang X, Mao H, Zhang N, Yu H, Pan J, Xie Y, Tang J, Yin S, Wang Z, Tong M, Zhan S, Wang C, Wang B, Zhang W, Mi W, Lu L.   +26 more
europepmc   +1 more source

Advances in Non-CPAP Management of Obstructive Sleep Apnea: Spotlight on Pharmacological Therapies. [PDF]

J Pers Med
Siciliano M, de Scisciolo M, Fratini A, Sottani C, Giordani F, Brunetti V.   +5 more
europepmc   +1 more source

Sarcoidosis and Obstructive Sleep Apnoea: An Intriguing Relationship. [PDF]

Open Respir Med J
Ciccarelli U, Ghelardini P, Pisciella MC, Zezza G, Nervoso A, Giordani F, Mari PV, Martone F, Siciliano M.   +8 more
europepmc   +1 more source

Pitolisant Improves Depressive Symptoms in CPAP-Treated Patients with Obstructive Sleep Apnea and Severe Residual Sleepiness: First 12-Month Clinical Experience. [PDF]

CNS Drugs
Caratozzolo D, Muscato G, Rizzo P, Gangemi C, Scionti A, Mancuso S, Vancheri C, Spicuzza L.   +7 more
europepmc   +1 more source